37 results
424B3
PHXM
PHAXIAM Therapeutics S.A.
29 Jun 23
Prospectus supplement
3:52pm
if, that matter is endorsed by the Board of Directors of the Company.
(c) There can be no assurance that Owners generally or any Owner in particular
6-K
EX-99.2
PHXM
PHAXIAM Therapeutics S.A.
24 May 23
Exemption Document Prepared In Connection with the Merger by Absorption of Pherecydes Pharma by Erytech Pharma
8:25am
reasonable assurance that the annual financial statements as a whole are free of material misstatement. Reasonable assurance is a high level of assurance
6-K
EX-99.1
PHXM
PHAXIAM Therapeutics S.A.
28 Apr 22
Asset Purchase Agreement
8:30am
, Manufacturing, MSAT, Quality Assurance, Quality Control, Quality Systems, Quality Suppliers, Supply Chain and US-Philadelphia ARC and exclude expenses that Seller
6-K
EX-10.3
fsub93q9qkttcinnc8
16 Dec 21
Erytech Announces Presentation of Results of Expanded Access Program In All at 2021 Ash Annual Meeting and Acceptance of Two Abstracts at Asco Gi
5:23pm
424B5
r6np76spm zo8s
16 Dec 21
Prospectus supplement for primary offering
5:21pm
F-3
2ri 1krh2bof
21 Sep 21
Shelf registration (foreign)
12:50pm
424B5
xbsqjk5djm4uwd9
5 May 21
Prospectus supplement for primary offering
4:50pm
6-K
EX-10.3
gv89p5kkr9a7bomk
3 May 21
ERYTECH Announces $30.0 Million
5:20pm
424B5
6zjf6qh3ukl2lu
3 May 21
Prospectus supplement for primary offering
5:14pm
424B5
caa5q7z0wjc
9 Oct 20
Prospectus supplement for primary offering
5:16pm
F-3
EX-1.2
5srt110
21 Sep 20
Shelf registration (foreign)
5:26pm
F-3
EX-4.2
qhb7i
21 Sep 20
Shelf registration (foreign)
5:26pm